Masofaniten
Term · Oncology and biomedicine · MLC-T-ONC-015017
An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, masofaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. Masofaniten may be more active and metabolically stable than first-generation AR NTD inhibitors.
| Identifier | MLC-T-ONC-015017 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | AR inhibitor EPI-7386; androgen receptor inhibitor EPI-7386 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015017",
"term": "Masofaniten",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, masofaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. Masofaniten may be more active and metabolically stable than first-generation AR NTD inhibitors.",
"synonyms": [
"AR inhibitor EPI-7386",
"androgen receptor inhibitor EPI-7386"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/masofaniten/"
}
Record 10,648 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.